阿拉瑞林与小剂量利维爱联合应用治疗子宫内膜异位症合并不孕症的研究被引量：9

Alarelin and low dose tibolone therapy for infertile patients with endometriosis

下载PDF

导出

摘要目的:探讨阿拉瑞林与小剂量利维爱(替勃龙)联合应用治疗子宫内膜异位症合并不孕症的疗效及其耐受性。方法:研究对象为1998年1月～2001年6月期间在我院诊治的40例子宫内膜异位症合并不孕症患者。实验组给以阿拉瑞林及利维爱,对照组单用阿拉瑞林。结果:用药后两组患者血清E2、P、FSH、LH水平及AEMAb、CA125阳性率均明显下降;症状体征明显改善;在治疗结束后6个月,实验组中55％、对照组中45％患者妊娠,两组间差异无统计学意义(P>0.05)。实验组未出现低雌激素症候群,而对照组中85％患者出现该症候群,两组差异有统计学意义(P<0.05)。结论:阿拉瑞林与小剂量利维爱联合应用不仅疗效好,而且副作用小。 Objective:To study the role of Alarelin plus low dose tibolone in the treatment of endometriosis.Methods:Fourly infertile patients with endometriosis were randomly divided into two goups.The patients in experimental group (n=20) received Alarelin 150μg/d and tibolone 1.25mg/d,and those in control group(n=20)received Alarelin 150μg/d alone.Results:Serum E2,P,FSH and LH levels were suppressed in all patients,and the positive rates of serum AEMAb and CA125 dropped markedly. Most patients showed significant improvement in clinical symptoms and signs.The pregnancy rate was 55% in experimental group and 45% in control group within 6 months of ceasing treatment,and there was no significant difference between the two groups(P>0.05).Hypoestrogenic side effect occurred in 85% of the patients in control group but did not happened in experimental group(P<0.05).Conclusion:Alarelin plus low dose tibolone has good curative efficacy with little side effect in the treatment of endometriosis.

作者张友忠许燕雪李晓梅

机构地区山东大学齐鲁医院妇产科

出处《山东大学学报（医学版）》 CAS 2004年第2期165-168,共4页 Journal of Shandong University:Health Sciences

关键词子宫内膜异位症不育促性腺素释放激素替勃龙 Endometriosis Infertility Gonadorelin Tibolone

分类号 R711.71 [医药卫生—妇产科学] R711.6 [医药卫生—妇产科学]

引文网络
相关文献

参考文献9

1Falcone T, Mascha E. The elusive diagnostic test for endometriosis[J]. Fertil Steril, 2003, 80(4):886.
2Blumenthal RD, Taylor A, Samoszuk M, et al. Unique molecular markers in human endometriosis: Implications for diagnosis and therapy [J]. Expert Rev Mol Med, 2001, 3:1.
3Gianetto-Berrutti A, Feyles V. Endometriosis related to infertility[J]. Minerva Ginecol, 2003, 55(5):407.
4Pritts EA, Taylor RN. An evidence-based evaluation of endometriosis-associated infertility [J]. Endocrinol Metab Clin North Am, 2003, 32(3):653.
5Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial [J]. Eur J Obstet Gynecol Reprod Biol, 2000, 88(1):11.
6Gnoth CH, Godtke K, Freundl G, et al. Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists[J]. Gynecol Obstet Invest, 1999, 47(1):37.
7Speroff L, Clarkson TB. Is tibolone a viable alternative to HT? [J]Contemporary OB/GYN, 2003, 48:4.
8Palomba S, Di Carlo C, Morelli M, et al. Effect. of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy[J]. Maturitas, 2003, 45(4):267.
9Gokaslan H, Oktem O, Durmusoglu F, et al. Apoptosis in the endometrium of postmenopausal women receiving tibolone[J]. Gynecol Obstet Invest, 2003, 6(3):124.